Chart pattern: Triple Bottom (weekly)
▲ Broken out
Broke on Nov 06, 2026 · measured target $97.41 (+8%). Details →
Nov 4, 6:01 AM ET
LivaNova reported third-quarter 2026 revenue of $393.1 million, up 9.9% from a year earlier, and raised its full-year 2026 constant-currency revenue growth range to 9% to 10% and its adjusted diluted EPS range to $4.40 to $4.50. GAAP diluted EPS fell to $0.11 from $0.49, reflecting $34.0 million of other operating expense, so shareholders face a mix of stronger underlying results and a lower reported profit.
- Q3 2026 revenue was $393.1 million, up 9.9% reported and 10.0% constant-currency; Cardiopulmonary rose 10.9% and Neuromodulation rose 11.1%.
- Q3 2026 GAAP diluted EPS was $0.11 versus $0.49 a year earlier; adjusted diluted EPS was $1.23 versus $1.11.
- Full-year 2026 constant-currency revenue growth guidance rose to 9% to 10% from 8% to 9%.
- Full-year 2026 adjusted diluted EPS guidance rose to $4.40 to $4.50 from $4.30 to $4.40; adjusted free cash flow guidance of $140 million to $160 million was maintained.
Read the filing on SEC.gov ↗
Aug 5, 6:05 AM ET
LivaNova reported second-quarter 2026 revenue of $390.6 million, up 10.8% from a year earlier, and adjusted diluted EPS of $1.26 versus $1.05. It raised its full-year 2026 revenue growth and adjusted EPS guidance but lowered its adjusted free cash flow guidance to $140 million to $160 million. For shareholders, the results show top-line and adjusted profit growth alongside a lower cash flow outlook, and GAAP operating income declined.
- Q2 2026 revenue was $390.6 million, up 10.8% reported and 9.8% constant-currency, from $352.5 million in Q2 2025.
- GAAP diluted EPS was $1.93 versus $0.50, including a discrete tax benefit of $95.4 million from an Italian tax authority ruling; adjusted diluted EPS was $1.26 versus $1.05.
- GAAP operating income was $49.5 million versus $54.2 million a year earlier; adjusted operating income was $90.8 million versus $77.4 million.
- 2026 guidance: constant-currency revenue growth raised to 8% to 9% (from 7% to 8%) and adjusted EPS raised to $4.30 to $4.40 (from $4.20 to $4.30); adjusted free cash flow lowered to $140 million to $160 million (from $160 million to $180 m
Read the filing on SEC.gov ↗
May 6, 6:02 AM ET
LivaNova reported first-quarter 2026 revenue of $362.3 million, up 14.3% from a year earlier, and raised its full-year 2026 revenue and adjusted diluted earnings per share guidance. GAAP diluted EPS was $0.40, compared with a loss of $6.01 a year earlier that included a $360.4 million SNIA environmental liability expense, and adjusted diluted EPS rose to $0.98 from $0.88.
- Q1 revenue of $362.3 million rose 14.3% reported and 11.1% in constant currency; Cardiopulmonary revenue rose 18.3%.
- GAAP diluted EPS was $0.40 versus a loss of $6.01 in Q1 2025; adjusted diluted EPS was $0.98 versus $0.88.
- 2026 adjusted diluted EPS guidance raised to $4.20 to $4.30 from $4.15 to $4.25; revenue growth guidance raised to 7.0% to 8.0% from 6.0% to 7.0% in constant currency.
- FDA granted premarket approval for the aura6000 System for moderate to severe obstructive sleep apnea.
Read the filing on SEC.gov ↗
Feb 25, 6:05 AM ET
LivaNova reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year revenue rose 10.7% to $1.39 billion and adjusted diluted EPS reached $3.90, but a $365.6 million SNIA environmental liability expense produced a GAAP diluted loss of $4.45 per share. The company expects 2026 adjusted diluted EPS of $4.15 to $4.25, which sets the earnings outlook shareholders will track in the coming year.
- Fourth-quarter 2025 revenue was $360.9 million, up 12.1% on a reported basis; GAAP diluted EPS was $0.56 versus $1.02, and adjusted diluted EPS was $0.86 versus $0.81.
- Full-year 2025 revenue was $1.39 billion, up 10.7%; GAAP diluted loss was $4.45 per share, including the $365.6 million SNIA charge, and adjusted diluted EPS was $3.90 versus $3.38.
- 2026 guidance calls for constant-currency revenue growth of 6.0% to 7.0%, adjusted diluted EPS of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million.
- Increased CMS reimbursement for VNS Therapy for drug-resistant epilepsy takes effect January 1, 2026, with hospital outpatient payments rising about 48% for new patient implants.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.